In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

Clinical Trials Search Results

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 37 for your search:
Drug:  veliparib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Start Over
        Show
1.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NABTT-0801 CDR0000616542, U01CA062475, ABTC-0801, NABTT-0801, ABBOTT-M10-190, 0801, NCT00770471

2.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-00312, MAYO-MC0861, 09-000742, CDR0000657976, MC0861, 8329, P30CA015083, U01CA069912, NCT01012817

3.

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RTOG-0929, CDR0000660545, NCT01026493

4.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M10-440, 2008-004941-27, NCT00804908

5.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 09-261, NCT01009788

6.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2009-170, NCT01051596

7.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M10-757, 2009-015082-31, NCT01113957

8.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01379, CHNMC-PHII-96, CDR0000674384, PHII-96, 8264, N01CM00032, N01CM62201, N01CM00071, P30CA033572, N01CM00039, N01CM00099, N01CM62209, N01CM00038, N01CM62203, NCT01149083

9.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M12-273, NCT01193140

10.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2009-268, NCT01205828

11.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02659, GOG-0127W, CDR0000691281, U10CA027469, GOG-0127W_2010-12-14, NCT01266447

12.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110080, 11-C-0080, NCT01306032

13.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-00684, GOG-0280, CDR0000726699, U10CA027469, NCT01540565

14.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M10-898, 2011-003427-36, NCT01560104

15.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M10-897, 2011-003618-18, NCT01657799

16.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-06-C-0172, NCI-P6890, 7675, NCT00387608

17.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-07-C-0203, P7241, 7981, NCT00553189

18.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00258, PCI-07-015, CDR0000566233, UPCI # 07-015, 7967, U01CA099168, N01CM00038, P30CA047904, 07-015, NCT00535119

19.

Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M06-862, NCT00526617

20.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00259, CDR0000579626, J0783, 7968, U01CA070095, U01CA069912, U01CA062491, P30CA006973, JHOC-J0783, NCT00588991

21.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: Over 18
Sponsor: NCI
Protocol IDs: NCI-2009-01057, CDR0000579642, 2007-014, 7977, P30CA022453, U01CA062490, U01CA062487, WSU-2007-014, NCT00576654

22.

Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M10-128, NCT00649207

23.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00262, CDR0000600234, 050803, 7998, P30CA072720, UM1CA186716, U01CA132194, U01CA099118, CINJ-050803, NCT00740805

24.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-09-C-0048, 09-C-0048, 8275, P8437, NCT00810966

25.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01472, CINJ-050810, CDR0000641433, U01CA062505, UPCI 08-121, U01CA099168, 08-121, 8282, P30CA047904, U01CA132194, UM1CA186690, UM1CA186717, UM1CA186716, NCT00892736
1   
New Search